leadf
logo-loader
viewOrthocell Ltd

Orthocell preparing for launch in the US for its CelGro® bone regeneration product

Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott following the news they've completed a submission to the US Food and Drug Administration (FDA) seeking 510(k) clearance for marketing its CelGro® product for dental guided bone and soft tissue regeneration applications.

''We are now starting to build our key opinion leader network in the US so that we're very highly focused, have the right people on board ... and we're moving towards product launch preparation as of today effectively''.

Anderson also updates on the nerve and tendon indications for CelGro® which they're advancing in parallel to the commercialisation of Ortho-ATI® and pipeline products.

Quick facts: Orthocell Ltd

Price: 0.36 AUD

ASX:OCC
Market: ASX
Market Cap: $66.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell 'in exciting regulatory phase' as it looks to drive its...

Orthocell Ltd's (ASX:OCC) Paul Anderson says the company's in an exciting regulatory phase having validated its technologies in the clinic and defining pathways to market through the US FDA process. ''We have some significant milestones ahead of us - we have an application within the FDA at the...

on 22/9/20

2 min read